MyWMCC WMCC Taste of Hope Cookbook
Visit WMCC on Facebook

WMCC Welcomes New Mid Level Providers

November 8th, 2011 by Lynne Emons

Kalamazoo, MIWest Michigan Cancer Center, a collaboration of Borgess Health and Bronson Healthcare Group, is pleased to announce the addition of five new mid-level providers to its staff at the main campus in Kalamazoo.

Laura Mullins, RN, MSN, CPNP, CPON, is a Certified Genetic Educator through the Oncology Nursing Society and a Certified Nurse Practitioner. She provides genetic counseling as a practitioner in collaboration with other members of the patient’s health care team. Mullins works directly with patients to provide assessments, counseling, follow-ups and referrals to community resources, if necessary.

A graduate of the Grace Hospital School of Nursing inDetroit, Mullins continued her education and received a Bachelor of Science in Nursing from the University of Michigan and a Master of Science in Nursing from Grand Valley State University.

Julie DiGiovanni, PA-C, is a Physician Assistant in our gynecologic oncology department, working directly with patients of Dr. Anna Hoekstra.

DiGiovanni received a Bachelor of Science degree from Western Michigan University and a Master of Science degree in Physician Assistant Studies from A.T. Still University in Mesa, Arizona.

Steve Stone, PA-C, and Jill Noack, PA-C, are Physician Assistants in our medical oncology department who see patients at both Bronson Methodist Hospital and Borgess Medical Center.

Stone received his Bachelor of Science degree, Master of Science in medicine degree and a Certificate in Physician Assistant Studies from Western Michigan University in Kalamazoo. His responsibilities include seeing and evaluating hematology, medical and radiation oncology patients and conducting consultations.

Noack received a Bachelor of Science degree from Ferris State University in Big Rapids, Michigan and a Bachelor of Science, Medicine, Physician Assistant Program, from the University of Iowa in Iowa City. Her responsibilities include seeing and evaluating hematology, medical and radiation oncology patients and conducting consultations.

Tricia Miedema, PA-C, is a Physician Assistant in our radiation oncology department, working directly with patients of Drs. Salvador Espinoza, Linda Grossheim and Vera Nigrin.   

Miedema received a Bachelor of Arts in Chemistry from Hope College.  She earned a Master of Science in Medicine degree and a Certificate in Physician Assistant Studies from Western Michigan University in Kalamazoo.  Her responsibilities include working directly with each of the physicians in pre and post radiation management of patients.

Time to Get A Flu Vaccine

September 22nd, 2011 by WMCC

Joseph Mirro, MD–WMCC President/CEO/CMO

At this time of the year, when the weather gets cooler, some people think of a beautiful fall, some look forward to football or the World Series (even if you are a Tigers’ fan) other start worrying about the snow but I am unusual in that I worry about the flu. I want to take an opportunity to remind everyone that it’s time to think about getting a flu shot. This is a critically important activity for all of us as it keeps us healthy and prevents the spread of flu. However, it is much more important in the cancer center because our patients are at a much higher risk for adverse events should they acquire the flu.

If you are a patient and you are not allergic, you should talk to your treating physician (either in the cancer center or your primary care doctor) about receiving a flu vaccination.  Even patients on chemotherapy will have an immunological response and be at least somewhat protected against the adverse effects of the flu. WMCC can provide vaccinations to patients at the center.  However, they should check with their insurance carrier first before having vaccines administered at WMCC—some plans do not provide coverage for preventative vaccines. 

The Centers for Disease Control and Prevention (CDC) recommend that everyone six months and older get a flu vaccine.  The 2011-12 flu vaccine will prevent against three different flu viruses:  an H3N2 virus, an influenza B virus and the H1N1 virus. 

At WMCC, we work very hard to immunize 100% of our employees. This year, we will also be providing the flu vaccine to our volunteers.  I also encourage everyone to speak with their family members.  Since we all want to protect our loved ones, urging them to be immunized will help them stay healthy and reduce everyone’s risk of the flu. What a wonderful opportunity to help the ones we love.

 

WMCC Welcomes New Physician

August 17th, 2011 by Lynne Emons

Kalamazoo, MI – West Michigan Cancer Center, a collaboration of Borgess Health and Bronson Healthcare Group, is pleased to announce the addition of a new radiation oncologist to its staff at the main campus in Kalamazoo.

Vera Nigrin, MD,  joins WMCC after spending eight years as a radiation oncologist in Nebraska and Washington.    

Dr. Nigrin earned her undergraduate and medical degrees from the University of Alberta, Edmonton in Canada.  She completed her residency at Kansas University Medical Center, Kansas City, and two radiation oncology fellowships—the first at the University of Louisville, Kentucky, and the second at Thomas Jefferson University Hospital in Philadelphia.

Dr. Nigrin is board certified in radiation oncology and is a member of the American Board of Radiology and the American Society for Therapeutic Radiology and Oncology.  She has special interests in image-guided radiotherapy, prostate brachytherapy and stereotactic radiosurgery.

WMCC Announces Leadership Transition

June 15th, 2011 by Lynne Emons
 

Terry McKay & Dr. Joe Mirro

West Michigan Cancer Center, a collaboration of Borgess Health and Bronson Healthcare Group, has appointed Joseph Mirro, MD, to the dual role of Chief Executive Officer (CEO) and Chief Medical Officer (CMO).  He replaces founding CEO Terry McKay, who will retire July 17th.

A distinguished pediatric oncologist and educator, Dr. Mirro brings to WMCC more than 35 years experience in oncology and healthcare leadership, most recently as Vice President of Cancer Services at Milwaukee, Wisconsin-based Aurora Health Care.  Prior to that, he served as a pediatric oncologist, medical school professor and administrator at St. Jude Children’s Research Hospital in Memphis, Tennessee.  

WMCC’s strong foundation and reputation for excellence in serving the cancer patients across Southwest Michigan drew Dr. Mirro to Kalamazoo.  “I am excited to join the outstanding staff at WMCC and help provide the patients we serve with unsurpassed cancer care,” Mirro said.  “I am honored to become associated with two excellent health care systems; and will do everything I can to advance the mission of both Bronson and Borgess so that every person in and around Kalamazoo can receive the best medical treatments available anywhere. Additionally, the opportunity to contribute to the academic mission of the new medical school makes this position at WMCC perfect”.

The search committee’s decision to select Dr. Mirro for the combined CEO/CMO position reflects WMCC’s continuing commitment to clinical excellence in cancer care. Frank Sardone, president and CEO of Bronson Healthcare, said he applauds current CEO Terry McKay for her many years of leadership and sees Dr. Mirro as the perfect choice as WMCC moves forward. “Dr. Mirro’s unique combination of administrative, clinical and academic leadership skills will enable him to make the most of this area’s superb medical resources. This is the right time for a physician leader to engage providers, academia and the hospitals in delivering world-class cancer care to our community.” 

Current CEO Terry McKay has led the organization for 17 years, from its inception through its steady ascent to a top performing community cancer center.  Today, WMCC averages nearly 80,000 patient visits annually and has earned numerous distinctions for clinical excellence.  Paul Spaude, CEO of Borgess Health, said with McKay’s leadership, the community has been the beneficiary of technology usually available only at university research hospitals. “Over the years, Terry McKay has been a remarkable force,” said Spaude.  “She’s grown the capabilities of the organization, and ensured the community always had every advantage that technology and talent would permit.”

Spaude added that McKay leaves the Cancer Center in an excellent position, poised and ready for a projected growth in patients due to the aging baby boom population.  Teamwork, collaboration and a commitment to delivering the highest quality care to patients are the reasons WMCC is positioned for the future, according to McKay.    “We are very fortunate to have such highly skilled, compassionate people, taking good care of every patient, every time, every day”, said McKay.  “It has been an absolute joy to work with everyone and an honor to create an organization that I envision as the ultimate environment and culture to care for cancer patients.    In 17 years, there was never a day that I didn’t enjoy coming to work,” added McKay. 

Adjuvant Breast Carcinoma

May 12th, 2010 by WMCC

ER = Estrogen Receptor, PR = Progesterone Receptor

TNM Staging: T = Tumor, N = Nodal status, M = Metastasis

Disease Stage
Lobular Carcinoma in Situ (LCIS) NONE
Ductal Carcinoma in Situ (DCIS) NONE
Completion of 5 years of Hormonal Therapy NSABP B-42: Five years of Letrozole versus Placebo (Can enroll while taking the Letrozole in years 3-5 and will the Letrozole will be provided)
ER & / or PR Positive Nodes Negative PACCT-1 ONCOTYPE DX Assay

Recurrance Score <11 Hormonal therapy, Recurrence Score 11-25 Hormonal Therapy versus Chemotherapy / Hormonal therapy, Recurrence Score > 25 Hormonal Therapy / Chemotherapy

Stage I / II/ III CTSU S0307: Zolendronic Acid versus Clodronate versus Ibandronate
Stage 0, I, or II ER/PR Negative–receiving 3 – 8 months of an alkylating agent Pre-Menopausal Only–ECOG S0230 Hormonal treatment during chemotherapy to reduce ovarian failure following chemotherapy
Stage 0,I or II (tumor must be 3cm or smaller)—Must have had prior lumpectomy, up to 3 axillary nodes can be histologically positive NSABP B-39: Whole Breast Irradiation (25 treatments in 5 weeks) versus Partial Breast Irradiation (10 treatments in 5 days)
Any T, Any N, M0 ER and/or PR positive, must be 6 months from chemotherapy completion (if given)–PRE-MENOPAUSAL WOMEN ONLY CTSU IBSCG 24-02: Tamoxifen for 5 years versus Ovarian Function Suppression (either using drugs / Radiation Therapy / surgery) plus Tamoxifen for 5 years versus Ovarian Function Suppression plus Exemestane for 5 years
T1a – 3, N0 – 3

ER / PR Negative

HER2 Negative

Bo20289 BEATRICE: Chemotherapy (Physician Choice) plus Bevacizumab
T1-3, N0-3 and HER2 Positive

If Node Negative, must have one of the following:

Tumor size > 2cm

ER / PR negative

Histologic &/or nuclear grade 2 or 3

Age < 35 years

NSABP B-44 (BETH): Docetaxel + Carboplatin + Trastuzumab (every 3 weeks for 6 cycles. This is given with or without Bevacizumab. Followed by continued Trastuzumab for a complete year of treatment (if Bevacizumab) was given initial, that will continue also for the entire year.
HER 2 positive

Node positive

If Node Negative, tumor size must be > / = 1cm

Prior treatment with at least 4 cycles of an Anthracycline

CTSU N063D (ALTTO) : After the inital chemotherapy the following will occur:

Tratuzumab every 3 weeks for 52 weeks versus Lapatinib orally for 52 weeks versus Tratuzumab every 3 weeks for 12 weeks, then 6 weeks off and then Lapatinib orally for 34 weeks versus Tratuzumab every 3 weeks and Lapatinib orally for 52 weeks.

If Paclitaxel is given, it will be weekly for the first 12 weeks. During this time, the Tratuzumab will also be given weekly.

HER 2 negative & must have one of the following:

At least one node positive

ER negative & tumor size > / = 1cm

ER Positive & tumor size > / = 5cm

ER positive & tumor size < / = 1cm, but < 5cm with a recurrence score of > / = 11

ECOG E5103 Adriamycin + Cytoxan (either every 2 weeks or every 3 weeks) plus Bevacizumab / placebo (4 cycles) followed by Paclitaxel plus Bevacizumab / placebo (4 Cycles). One group will continue the Bevacizumab every 3 weeks for a total of 10 more cycles.
Core biopsy only & Greater than or equal to 2.0cm tumor size & HER2 Negative

Core biopsy only & Greater than or equal to 2.0cm tumor size & HER2 Positive

HER2+, locally advanced-NeoAdjuvant OR Stage III after surgery

NSABP B-40: Docetaxel + Adriamycin / Cytoxan (AC) with or without Bevacizumab Versus Docetaxel + Capecitabine + AC with or without Bevacizumab Versus Docetaxel + Gemzar + AC with or without Bevacizumab, then surgery and continued Bevacizumab if received before.

NSABP B-41: Adriamycin + Cytoxan (AC) followed by Trastuzumab + Lapatinib versus + Lapatinib + weekly Paclitaxel

NSABP FB-05 Epirubicin + Cyclophosphamide, then Docetaxel + Herceptin + Bevacizumab

Stage II / III, ER+, Postmenopausal–NeoAdjuvant CTSU Z1031: 16 weeeks versus 18 weeks of Exemestane, Letrozole or Anastroxole
First local and/or regional recurrence NSABP B-37: Observation with or without Radiation, Hormonal therapy, and/or Herceptin versus Chemotherapy (selected by the physician) with or without Radiation, Hormonal therapy, and/or Herceptin

Regional & Metastatic Breast Carcinoma

May 12th, 2010 by WMCC

ER = Estrogen Receptor, PR = Progesterone Receptor

Disease Stage No Prior Treatment for Metastatic Disease Prior Treatment for Metastatic Disease
Stage IV ECOG E1105: Paclitaxel, Carboplatin, and Trastuzumab plus Bevacizumab or Placebo Versus Paclitaxel and Trastuzumab plus Bevacizumab or Placebo

CTSU S0226: Anastrozole versus Anastrozole and Fulvestrant–Must be post menopausal

CTSU S0550: Circulation Tumor Cell (CTC) levels–used to determined wether the chemotherapy should be modified

GENENTECH TDM4450g: Trastuzumab-MCC-DM1 versus Trastuzumab and Docetaxel

CTSU C40502: Weekly Paclitaxel versus weekly albumin bound nad-paclitaxer or Ixabepilone with Bevacizumab

Pfizer A6181068–Any HER 2 status, any ER / PR–Single agent Sunitinib

ECOG E1104–HER2 +, any ER / PR–Suberoylanilide Hydroxamic Acid (SAHA, Vorinostat) + Herceptin with or without chemotherapy–Locally advance recurrence is OK (SUSPENDED 10/07)

CTSUN0733–HER2+, Previously treated with Trastuzumab and anthracycline or taxane–Capecitabine and Lapatinib + / – IMC-A12

GENENTECH TDM4374g: Trastuzumab-MCC-DM1

Post menopausal only & ER positive and / or PR positive

1-2 prior endocrine treatment, may have one prior chemo–CTSU C40302–HER +, ER+ /PR– Fulvestrant + Lapatinib versus Fulvestrant + Placebo

CTSU C40503: Hormonal therapy + / – Bevacizumab

Central Nervous System

May 12th, 2010 by WMCC
Site Protocol Title/Description
Anaplastic Astrocytoma NONE
Glioblastoma Multiforme

Recurrent Glioblastoma Multiforme

MDA 2004-0062: Prior Radiation Therapy within 5 weeks required. Temozolomide (TMZ) versus TMZ plus Thalidomide versus TMZ plus Celecoxib versus TMZ plus Thalidomide plus Isotretinoin versus TMZ plus Thalidomide plus Celecoxib versus TMZ plus Isotretinoin plus Celecoxib versus TMZ plus Thalidomide plus Celecoxib

RTOG 0513: Temozolomide, Motexafin Gadolinium and Radiation Therapy

RTOG 0627: Dasatinib (Suspended 10/07)

RTOG 0625: Bevacizumab with irinotecan versus temozolomide

Primary CNS Lymphoma ECOG E1F05: Rituximab in conjunction with standard chemotherapy

RTOG 0227: Pre-irradiation Chemotherapy (Methotrexate / Rituximab / Temozolomide) and Post Irradiation Temozolomide

Primary NonSmall Cell Lung Cancer Brain Metastases RTOG 0320: (1 to 3 lesions) Whole Brain and Stereotactic Radiation Therapy versus Whole Brain and Stereotactic Radiation Therapy, Temozolomide or Gefitinib
Brain Metastases CTSU 0574: Whole Brain Radiation Therapy plus Radiosurgery (1-3 Cerebral Metastases)
Grade II Astrocytoma Oligoastrocytoma Oligodendroglioma RTOG 0424: High Risk, Low Grade—Temozolomide with Concurrent Radiation Therapy

Gastrointestinal System

May 12th, 2010 by WMCC

TNM Staging: T = Tumor, N = Nodal Status, M = Metastasis

Sites Adjuvant Locally Unrestable Metastatic/Measurable
Esophagus Neo-Adjuvant:

ECOG E2205: Radiation Therapy with Oxaliplatin, continuous infusion 5FU and Cetuximab the surgery followed by Docetaxel and Cetuximab

ECOG 80403: Epirubicin, Cisplatin, Continuous Infusion 5FU and Cetuximab (ECF-C) versus Irinotecan, Cisplatin and Cetuximab (IC-C) versus Oxalipatin, Leucovorin, 5FU (FOLFOX) and Cetuximab

RTOG 0436: Cetuximab, Paclitaxel, Cisplatin and Radiation Therapy

ECOG 80403: Epirubicin, Cisplatin, Continuous Infusion 5FU and Cetuximab (ECF-C) versus Irinotecan, Cisplatin and Cetuximab (IC-C) versus Oxalipatin, Leucovorin, 5FU (FOLFOX) and Cetuximab

Schering Plough P04273: Temozolomide for CA selected for methylation of O6 methyl-guanine DNA Methyl-transferase promoter–May have received one prior treatment

Gastric or GE Junction CTSU C80101: 5FU/Leucovorin & continuous 5FU/Radiation Therapy versus. Epirubicin/ Cisplatin/ 5FU & continuous 5FU/Radiation Therapy ECOG 80403: Epirubicin, Cisplatin, Continuous Infusion 5FU and Cetuximab (ECF-C) versus Irinotecan, Cisplatin and Cetuximab (IC-C) versus Oxalipatin, Leucovorin, 5FU (FOLFOX) and Cetuximab (Includes the GE Junction only) ECOG 80403: Epirubicin, Cisplatin, Continuous Infusion 5FU and Cetuximab (ECF-C) versus Irinotecan, Cisplatin and Cetuximab (IC-C) versus Oxalipatin, Leucovorin, 5FU (FOLFOX) and Cetuximab (Includes the GE Junction only)

Schering Plough P04273: Temozolomide for CA selected for methylation of O6 methyl-guanine DNA Methyl-transferase promoter–May have received one prior treatment

Pancreas None None None
Gastro-Intestinal Stromal Tumor (GIST) CST 15721BUS227: Registry Study

CTSU S0502: Imatinib with or without Bevacizumab

Unresectable Stage IV Colon Cancer NSABP C-10: mFOLFOX6 plus Bevacizumab
Colon ECOG E5202: (T3-4,N0, M0) Parafin tissue block sent for microsatellite instability & loss of heterozygosity at 18q–If low risk, then Observation and If high risk, then FOLFOX (Oxaliplatin / 5FU / Leucovorin) with or without Bevacizumab

Stage III: CTSU N0147: . FOLFOX (Oxaliplatin / 5FU / Leucovorin) with or without C225

None CTSU C80405: FOLFOX (Oxaliplatin / 5FU / Leucovorin) or FOLFIRI (Irinotecan / 5FU/ Leucovorin) with or without Bevacizumab

ECOG E4203: Treatment based on TS Expression:

High TS Expression: IROX + Bevacizumab versus FOLFOX + Bevacizumab

Low TS Expression: FOLFOX + Bevacizumab

Second Line Treatment:

CTSU S0600: Irinotecan based chemo + Cetuximab with or without Bevacizumab–2nd line treatment for patients whos hve progressed on Bevacizumab with either FOLFOX, OPTIMOX or XELOX (Suspended 6/08)

Rectum Pre operative treatments :

NSABP R-04: Radiation Therapy and Capecitabine, then Surgery versus Radiation Therapy and continous 5FU, then Surgery

Stage II or III – ECOG E5204: FOLFOX (Oxaliplatin / 5FU / Leucovorin) with or without Bevacizumab after surgery

ECOG E3204: RT + concurrent Capecitabine, Oxalipatin, and Bevacizumab then surgery and post operative FOLFOX and bevacizumab

None CTSU C80405: FOLFOX (Oxaliplatin / 5FU / Leucovorin) or FOLFIRI (Irinotecan / 5FU/ Leucovorin) with or without Bevacizumab
Anal None None

Genitourinary System

May 12th, 2010 by WMCC

PSA = Prostatic Specific Antigen

GS = Gleason Score

TNM Staging: T = Tumor, N = Nodal status, M = Metastasis

Site Stage/Description Protocol Title
Bladder Muscle invasive, non-cystectomy candidates RTOG 0524: Paclitaxel and trastuxumab with daily RT versus Paclitaxel alone with daily RT followed by transurethral surgery
Renal Insufficiency MDA 2005-0839: Gemcitabine, paclitaxel & Doxorubicin with Pegfilgrastim
Testicular None
Ureter or Urethra Advanced and prior treatment None
Prostate Localized, high risk with the one of the following:

GS>/=9 / PSA </=150 / any T GS 8 / PSA < 20 / > / = T 2 GS7-8 / PSA>/=20-150/Any T

RTOG 0521: Hormone suppression plus 3D Intense Modulated RadiationTherapy (IMRT) versus Hormone suppression plus 3D Intense Modulated Radiation Therapy (IMRT) followed by Doxetaxel and Prednisone.
T1c – T2b

GS 2 – 6 and PSA > / = 10

or

GS < 7 and PSA 10-20

or

GS 7 and PSA < 10

RTOG 0232: External Radiation Therapy with Brachytherapy versus Brachytherapy alone
Rising PSA RTOG 0534: Transperineal ultrasound guided brachytherapy following external beam radiotherapy

RTOG 0622: Samarium 153 the Radiation therapy after radical prostatectomy (Presently on Hold)

Locally Recurrent RTOG 0526: Transperineal ultrasound guided brachytherapy following external beam readiotherapy
Stage D2 None
Extensive Disease ECOG E3805 (CHAARTED): ChemoHormonal Therapy versus Hormonal Therapy Ablation

ECOG E5805: Halichondrin B analog (E7389) for hormone refractory

Hormone refractory CTSU S0421: Docetaxel & Astrasentan versus Docetaxel & Placebo

MDA ID00-156: Adriamycin/Ketoconazole alternating with Vinblastine / Estramustine OR Taxol / Estramustine with or without SR-89 plus 6 weeks of Adriamycin

ECOG E3803: BMS 247550–Must have received prior treatment with Taxane

ECOG E5805: Halichondrin B analog (E7389) for hormone refractory

Renal No Prior Treatment ECOG E4805: Two different doses of AVE0005 (VEGF Trap)–must have had ONLY one prior treatment with either Sutent or Nexavar for at least 12 weeks

ECOG E2805: Adjuvant Sunitinib versus Sorafenib versus Placebo

ECOG E2804 (BEST): VEGF, RAF Kinase & mTOR combo, targeted therapy with Bevacizumab + Sorafenib + Temsirolimus

Gynecologic

May 12th, 2010 by WMCC
Site Stage/Description Protocol Title
Cervix Treated with radical hysterectomy / lymph node dissection None
No prior treatment, limited to the pelvis: Stage IB2, IIA, IIB, IIIB, IVA None
One prior treatment (performance status 0 -2) GOG 127V: ABI-007 (Suspended)
Pelvic / para-aortic lymphademectomy GOG 221: Glycoprotein & Glycan profiling
Persistent or Recurrent GOG 0227E: Cetuximab
Vulvar Malignancies Locally advanced and squamous cell GOG 205: Radiation therpay and weekly Cisplatin

GOG 0173: Intraoperative lymphatic mapping & Sentinel node identification

Ovary Bone Mineral Denisty GOG 215: Zoledronic acid versus observation for women who have risk reducing surgery that removed both ovaries
Recurrent and Platinum sensitive GOG 213: Carboplatin and Paclitaxel versus Carboplatin, Paclitaxel and Bevacizumab, followed by Bevacizumab and cytoreductive surgery
Recurrent and Platinum resistant GOG 0126R: Abraxane
Stromal tumors GOG 187: Paclitaxel as second line therapy
Cancer of the Fallopian Tube Biochemical (Rising CA-125) recurrence only NONE
Recurrent and Platinum sensitive GOG 213: Carboplatin and Paclitaxel versus Carboplatin, Paclitaxel and Bevacizumab, followed by Bevacizumab and cytoreductive surgery
Recurrent and Platinum resistant GOG 0126R: Abraxane
Epithelial Ovarian/ Primary Peritoneal cancer Biochemical (Rising CA-125) Recurrence Only NONE
Suboptimal, residual disease–Stage III / IV GOG 0218: Carboplatin and Paclitaxel with Bevacizumab versus Carboplatin and Paclitaxel with Placebo
Complete response to primary Platinum / Taxane Chemotherapy GOG 0212: Paclitaxel once every 4 weeks for 12 treatments versus Xyotax once every 4 weeks X 12 treatment versus no further treatment
Recurrent and Platinum sensitive GOG 213: Carboplatin and Paclitaxel versus Carboplatin, Paclitaxel and Bevacizumab, followed by Bevacizumab and cytoreductive surgery
Recurrent and Platinum resistant GOG 0126R: Abraxane
Persistent/Recurrent GOG 170M: Dasatinib
Endometrial Stage IB (Grade 3), Stage IC (Grade 1-3), Stage IIA or IIB None
Stage III/IV GOG 0209: Doxorubicin / Cisplatinum / Paclitaxel / G-CSF versus Carboplatin / Paclitaxel

GOG 232C: Paclitaxel, Carboplatin and BSI-201

Recurrent / Persistent Disease No prior treatment GOG 0209: Doxorubicin / Cisplatinum / Paclitaxel / G-CSF versus Carboplatin / Paclitaxel

GOG 232C: Paclitaxel, Carboplatin and BSI-201

Any number of prior treatments GOG 188 Faslodex
Carcinosarcoma No prior treatment NONE
Prior treatments NONE
Leiomyosarcoma No prior treatments NONE
Prior treatments GOG 87M: Trabectedin Suspended